This test is a preferred screening test for patients suspected to have an autoimmune blistering disorder of the skin or mucous membranes (pemphigus). This test aids in the diagnosis of pemphigus. The antibody levels can be used to monitor the effectiveness of drug treatment.
Immediately following collection, thoroughly mix sample by gently inverting 5 times
Frozen (preferred) - 14 days
Ambient - 8 hours
Refrigerated - NO
Enzyme Immunoassay (EIA)
See report
Pemphigus diseases involve an autoimmune response primarily targeting desmoglein (Dsg) 1 and 3, which are cadherin-type transmembrane adhesion molecules. These desmogleins, in conjunction with desmocollins, play a crucial role in maintaining the cohesion between epidermal keratinocytes and are connected internally to the intermediate filament network through various plakins.
Pemphigus foliaceus (PF) is characterized by IgG autoantibodies against Dsg1, resulting in blistering limited to the upper skin, with no evident involvement of mucous membranes. On the other hand, pemphigus vulgaris (PV) primarily targets Dsg3 as the major autoantigen, but approximately 50% to 60% of patients also develop additional autoantibodies against Dsg1, leading to significant mucous membrane involvement.